Compare iShares iBoxx $ High Yield Corporate Bond ETF (HYG) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ High Yield Corporate Bond ETF vs GeneDx Holdings Corp — how do they compare? iShares iBoxx $ High Yield Corporate Bond ETF trades at $77.23 (market cap $17.89B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: iShares iBoxx $ High Yield Corporate Bond ETF is far larger — about 8.9× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, iShares iBoxx $ High Yield Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares iBoxx $ High Yield Corporate Bond ETF for 60 Days and GeneDx Holdings Corp for 19 Days on average.
| HYG | WGS | |
|---|---|---|
Market Cap | $17.89B | $2.02B |
Volume | 44,866,592 | 734,640 |
Sector | Fixed Income | Health |
52-Week High | $81.28 | $167.51 |
52-Week Low | $76.90 | $34.51 |
Typical Hold Time | 60 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HYG trades at $77.23 with minimal daily movement (+0.06%), showing stability amid broader market volatility. The technical picture remains bearish with moving averages signaling continued downward pressure, though oscillators suggest potential stabilization. Recent dividend payments provide consistent income, with the latest $0.38 distribution paid in August 2026. The fund faces headwinds from rising Treasury yields and bond market volatility, with key technical indicators showing mixed signals between short-term stabilization and longer-term bearish momentum.
High yield bond ETFs like HYG face pressure from rising interest rates and inflation concerns, though the fund's diversified corporate bond portfolio offers yield advantages over Treasury securities. The current environment presents both income opportunities through attractive yields and risks from potential credit deterioration if economic conditions worsen. Investors should weigh the fund's income generation against interest rate sensitivity and credit risk exposure in the current tightening cycle.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
